Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's Disease

NCT02048618 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

175

Enrollment

INDUSTRY

Sponsor class

Conditions

Crohn's Disease

Interventions

DRUG: GLPG0634
DRUG: Placebo

Sponsor

Lakefront Biotherapeutics NV